Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lynparza Poised For Growth With Broad Ovarian Cancer Approval

Aug 18 2017

OvarianCancer_1200x675

Related Content

AstraZeneca Mulls Broad Ovarian Cancer Maintenance Approval For Lynparza

Mar 15 2017

AstraZeneca's OlympiAD Trial Kick-Starts PARP In Breast Cancer

Jun 05 2017

Broad Label Gives Tesaro's Niraparib A Head Start In Ovarian Cancer

Mar 28 2017

The PARP Combo Race Is On: Clovis And Bristol Partner On Rubraca

Jul 31 2017

A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck

Jul 27 2017

Clovis's Rubraca Leapfrogs Rivals In Ovarian Cancer As ARIEL3 Hits

Jun 19 2017

Related Companies

AstraZeneca PLC

Merck & Co., Inc.

Tesaro, Inc.

Clovis Oncology, Inc.

Clovis Oncology, Inc.

Bristol Myers Squibb Company

Additional Topics

Approvals Research & Development Regulation Cancer BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window